The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor
Samantha Hinsley(University of Leeds), Gordon Cook(University of Leeds), Bryony Dawkins(University of Leeds), Sophie C. McKee(University of Leeds), Mark Cook(Université Paris Cité), Lucy Bailey(Oklahoma State University Oklahoma City), Holger W. Auner(University Hospital of Lausanne), Debbie Sherratt(University of Leeds), Sarah Brown(University of Leeds), Martin Kaiser(Royal Marsden NHS Foundation Trust), Katrina Walker(University of Leeds), David Meads(University of Leeds), Fiona Brudenell Straw(University of Leeds), Sadie Reed, Louise Flanagan(University of Leeds)
Cited by 4
Related Papers
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
|Blood|2020|657
Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial
|The Lancet|2010|640
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
|The Lancet|2010|571
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
|Journal of Clinical Oncology|2015|564